



PRESS RELEASE

Hikma wins Company of the Year at the Global Generics & Biosimilars Awards 2017

London, 3 November 2017 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with the Company of the Year Award at the Global Generics & Biosimilars Awards 2017.

"We are extremely proud to have received this recognition of the role we are play in providing quality, affordable medicines to improve health around the world. For nearly 40 years this has been our driving purpose, and it still motivates us everyday," said Said Darwazah, Chairman and CEO of Hikma.

-- ENDS --

Hikma Pharmaceuticals PLC

Brooke Clarke, VP Corporate Affairs

+44 (0)20 7399 2760/ +44 7970 338250

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'Injectables,' 'Generics' and 'Branded,' based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of \$1,950 million and profit attributable to shareholders of \$155 million.